Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 6/20 | 0.52 |
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.49 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 3/20 | 0.45 |
| ▸ | NPY2R | P49146 | 3/20 | 0.43 |
| ▸ | NPY4R | P50391 | 3/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.43 |
| ▸ | NPY1R | P25929 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29886085 | 0.90 | EPHA2 (0.49) | EPHA2NMUR2NMUR1CXCR4 | |
| SCHEMBL31633428 | 0.88 | CXCR4 (0.54) | NMUR2NMUR1CXCR4KDM1ANPY2R | |
| SCHEMBL8201749 | 0.87 | RAMP3 (0.52) | EPHA2NMUR2NMUR1KDM1A | |
| SCHEMBL8201752 | 0.87 | RAMP3 (0.52) | EPHA2NMUR2NMUR1KDM1A | |
| SCHEMBL30974543 | 0.87 | EPHA2 (0.43) | EPHA2NMUR2NMUR1 | |
| SCHEMBL891576 | 0.87 | CXCR4 (0.52) | EPHA2NMUR2NMUR1CXCR4 | |
| SCHEMBL2317896 | 0.87 | CXCR4 (0.48) | EPHA2NMUR2NMUR1CXCR4 | |
| SCHEMBL891575 | 0.87 | CXCR4 (0.52) | EPHA2NMUR2NMUR1CXCR4 | |
| SCHEMBL2317887 | 0.87 | CXCR4 (0.48) | EPHA2NMUR2NMUR1CXCR4 | |
| SCHEMBL28923776 | 0.87 | CXCR4 (0.48) | EPHA2NMUR2NMUR1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630640-B2 | Bispecific caninized antibodies for treating atopic dermatitis | INTERVET INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20230250177-A1 | Bispecific Caninized Antibodies for Treating Atopic Dermatitis | INTERVET INC. (US) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630640-B2 | Bispecific caninized antibodies for treating atopic dermatitis | IL4, IL33, IL36G | EPHA2 2024/4885NMUR2 3609/4885NMUR1 2505/4885 |
| US-20230250177-A1 | Bispecific Caninized Antibodies for Treating Atopic Dermatitis | IL5, ITCH, IL33 | EPHA2 920/4885NMUR2 3837/4885NMUR1 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.